# Optogenetic engineering of synthetic and natural receptors: design principles, functional mechanisms and biomedical applications

**Authors:** Jiaying Zhao, Yani Chen, BiCong Gao, Lujiao Zhang, Ning Gao, Sijia Hao, Zili Gao, Wenjin Cai, Jian Yang, Guoli Yang

PMC · DOI: 10.1093/rb/rbaf126 · Regenerative Biomaterials · 2025-12-17

## TL;DR

Optogenetic receptors use light to precisely control cell signaling, offering new ways to study and treat diseases by manipulating cellular communication.

## Contribution

This paper outlines design principles and applications of optogenetic receptors, emphasizing their potential for biomedical innovation.

## Key findings

- Optogenetic receptors allow precise, reversible control of signaling without disrupting endogenous pathways.
- They enable causal analysis of dynamic signaling and manipulation of neuromodulatory and immune circuits.
- Future integration with AI and materials science could improve optical fidelity and signal amplification in complex environments.

## Abstract

Cellular receptors serve as central hubs that translate external signals into intracellular programs governing cell fate, function and behavior. Achieving precise and reversible control over receptor activity has long been a major challenge in both fundamental biology and translational medicine. Optogenetic receptor engineering provides a transformative solution by integrating photosensitive domains into natural receptor frameworks. This strategy enables light-dependent modulation of signaling with high spatial and temporal precision while maintaining minimal disturbance to endogenous pathways. Unlike chemogenetic systems or classical photoreceptive ion channels, this approach preserves endogenous ligand specificity and avoids slow ligand diffusion/clearance-associated artifacts. Through such systems, researchers can dissect causal relationships in dynamic signaling events, finely manipulate neuromodulatory and immune circuits and program cellular activities involved in development and tissue regeneration. The approach also allows quantitative control of signaling intensity and duration, offering new opportunities for linking molecular design to physiological outcomes. By combining optogenetic principles with advances in materials science and bioelectronics, future designs may achieve improved optical fidelity, enhanced light penetration and better signal amplification within complex biological environments. Integration with AI-guided protein engineering may also accelerate the discovery of optimized photosensory–receptor pairings. Together, these developments point to an emerging field where light-responsive receptors function as programmable interfaces between photonic control and cellular computation. In summary, the engineering of optogenetic receptors establishes a conceptual and technological framework for reversible, accurate and tunable regulation of cellular communication. This review summarizes current progress, outlines key design principles and provides conceptual guidelines for advancing next-generation light-responsive receptors and their biomedical applications. However, key translational challenges—including immunogenicity of non-human photoreceptors, limited gene-delivery efficiency and long-term biosafety—remain to be addressed through nonviral delivery strategies, autologous cell engineering and de-immunized or humanized photoreceptor design.

## Full-text entities

- **Genes:** Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, CXADRP1 (CXADR pseudogene 1) [NCBI Gene 653108] {aka CAR, CXADRP}, Ntrk2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 25054] {aka RATTRKB1, TRKB1, Tkrb, trk-B, trkB}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CRY2 (cryptochrome circadian regulator 2) [NCBI Gene 1408] {aka HCRY2, PHLL2}, HSPG2 (heparan sulfate proteoglycan 2) [NCBI Gene 3339] {aka HSPG, PLC, PRCAN, SJA, SJS, SJS1}, PIF1 (PIF1 5'-to-3' DNA helicase) [NCBI Gene 80119] {aka C15orf20, PIF}, CD247 (CD247 molecule) [NCBI Gene 919] {aka CD3-ZETA, CD3H, CD3Q, CD3Z, CD3ZETA, IMD25}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, NTRK1 (neurotrophic receptor tyrosine kinase 1) [NCBI Gene 4914] {aka MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA}, EPOR (erythropoietin receptor) [NCBI Gene 2057] {aka EPO-R}, CIB1 (calcium and integrin binding 1) [NCBI Gene 10519] {aka CIB, CIBP, EV3, KIP1, PRKDCIP, SIP2-28}, Pik3cb (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta) [NCBI Gene 85243], TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, Ngf (nerve growth factor) [NCBI Gene 310738] {aka Ngfb, beta-NGF}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, ARRB1 (arrestin beta 1) [NCBI Gene 408] {aka ARB1, ARR1}, RHO (rhodopsin) [NCBI Gene 509933], ADRB2 (adrenoceptor beta 2) [NCBI Gene 154] {aka ADRB2R, ADRBR, ARB2, B2AR, BAR, BETA2AR}, ntrk1 (neurotrophic tyrosine kinase, receptor, type 1) [NCBI Gene 30546] {aka trk, trka}, GLUL (glutamate-ammonia ligase) [NCBI Gene 281199], NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}, CARS1 (cysteinyl-tRNA synthetase 1) [NCBI Gene 833] {aka CARS, CYSRS, MCDDBH, MDBH, MGC:11246}
- **Diseases:** Parkinson's disease (MESH:D010300), CRS (MESH:D000080424), depression (MESH:D003866), melanoma (MESH:D008545), cancer (MESH:D009369), fibrosis (MESH:D005355), cytotoxicity (MESH:D064420), lymphoma (MESH:D008223), neuroinflammatory (MESH:D000090862)
- **Chemicals:** flavin (MESH:C024132), azobenzene (MESH:C009850), ATP (MESH:D000255), retinal (MESH:D012172), CBCR (-), LiCAR-T (MESH:C064142), lipid (MESH:D008055)
- **Species:** Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913], Mus musculus (house mouse, species) [taxon 10090], Arabidopsis thaliana (mouse-ear cress, species) [taxon 3702], Danio rerio (leopard danio, species) [taxon 7955]
- **Cell lines:** LiCAR-T — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_3174), PC12 — Rattus norvegicus (Rat), Rat adrenal gland pheochromocytoma, Cancer cell line (CVCL_0481)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12826800/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12826800/full.md

## References

180 references — full list in the complete paper: https://tomesphere.com/paper/PMC12826800/full.md

---
Source: https://tomesphere.com/paper/PMC12826800